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The ability of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) to divide indeﬁnitely without
losing pluripotency and to theoretically diﬀerentiate into any cell type in the body makes them highly attractive cell sources for
large scale regenerative medicine purposes. The current use of adult stem cell-derived products in hematologic intervention sets
an important precedent and provides a guide for developing hESC/iPSC based therapies for the blood system. In this review,
we highlight biological functions of mature cells of the blood, clinical conditions requiring the transfusion or stimulation of
these cells, and the potential for hESC/iPSC-derivatives to serve as functional replacements. Many researchers have already been
able to diﬀerentiate hESCs and/or iPSCs into speciﬁc mature blood cell types. For example, hESC-derived red blood cells and
platelets are functional in tasks such as oxygen delivery and blood clotting, respectively and may be able to serve as substitutes
for their donor-derived counterparts in emergencies. hESC-derived dendritic cells are functional in antigen-presentation and may
be used as oﬀ-the-shelf vaccine therapies to stimulate antigen-speciﬁc immune responses against cancer cells. However, in vitro
diﬀerentiation systems used to generate these cells will need further optimization before hESC/iPSC-derived blood components
can be used clinically.
1.Introduction
Human embryonic stem cells (hESCs) have been touted as
the future of regenerative medicine due to their potential
to diﬀerentiate into any cell type in the body. Unlike adult
or cord blood stem cells, hESCs are capable of expanding
indeﬁnitely in culture without losing their pluripotency,
and this makes them an attractive cell source to be used
for the large-scale production of a variety of therapeutic
cell types [1]. The advent of human-induced pluripotent
stem cells (iPSCs) has added another dimension to the ﬁeld
of regenerative medicine as it may allow patient-speciﬁc
therapies to be produced, thus reducing issues with HLA
mismatching and immunoincompatibility [2]. While each
has its own advantages and disadvantages, hESCs and iPSCs
represent two pluripotent cell sources with far-reaching
clinical potential in treating neurologic disorders, repairing
orreplacingdamagedtissues,andasdetailedhere,producing
transfusable blood components.
Hematopoietic stem cells (HSCs) located within the
bone marrow normally give rise to and are responsible for
replenishing all mature cells within the adult blood system
[3]. HSCs initially diﬀerentiate into multipotent progenitors
(MPPs) and then diﬀerentiate further into common myeloid
progenitors (CMPs) and common lymphoid progenitors
(CLPs).CMPseventuallygiverisetoerythrocytes,megakary-
ocytes/platelets, monocytes, and granulocytes while CLPs
produce natural killer, T, and B cells (Figure 1). Researchers
have already been able to obtain highly enriched populations
of in vitro generated blood components by diﬀerentiating
hESCsand/oriPSCsdownparticularhematopoieticlineages.
Each of the mature cell types within the blood system can2 Stem Cells International
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Figure 1: Simpliﬁed schematic of hematopoietic diﬀerentiation. At the top, hESCs and/or iPSCs may be able to recapitulate hematopoietic
diﬀerentiation in vitro after initial diﬀerentiation into EBs and/or HBs intermediates. These culture-based intermediates diﬀerentiate into
cells similar to mesoderm-derived HSC/progenitors. The boxed region shows hematopoietic diﬀerentiation as it is thought to occur in vivo.
HSCs undergo successive stages of diﬀerentiation to give rise to progenitor cells in both the myeloid lineage (left side) and lymphoid lineage
(right side). These progenitors will undergo further diﬀerentiation to eventually give rise to mature cells within the peripheral blood.
be used for distinct clinical purposes, and this paper will
focus on the ability of hESCs/iPSCs to serve as substitutes
for primary cells in these endeavors.
2.RedBloodCells
Erythrocytes or red blood cells (RBCs) are the most plen-
t i f u lc e l lt y p ei nt h ep e r i p h e r a lb l o o da n da r ep r e s e n ta t
a concentration of 5 × 1012 cells/liter(L) [4], which accounts
for approximately 40%–45% of the total blood volume
(Figure 2)[ 4, 5]. Despite the body’s seemingly abundant
capacity to produce RBCs, approximately 16 million units
of RBCs are collected and transfused annually into patients
[6],includingthosesuﬀeringfromanemia(lowRBCcounts)
or massive blood loss due to trauma. Type (O)Rh-negative
“universal” RBCs are highly desirable for emergency situa-
tion where blood typing may not be possible and are usually
the ﬁrst to be depleted when clinics encounter shortages in
their supplies. The derivation of (O)Rh-negative RBCs from
hESCs/iPSCs clearly oﬀers an attractive option foralleviating
the constant shortage in donated RBCs.
Deﬁnitive erythropoiesis in the adult bone marrow is
a multistep process regulated by the cytokine, erythropoietin
(EPO). It begins when an HSC-derived CMP passes through
the megakaryocyte erythrocyte progenitor (MEP) stage and
commits to the erythroid lineage. The appearance of the
pronormoblast (also called proerythroblast or rubriblast)
marks the ﬁrst stage of diﬀerentiation and is subsequently
followed by early, intermediate, and late normoblast (ery-
throblast) stages, at which time the nucleus is expelled
and the cell becomes a reticulocyte. Reticulocytes exit the
bone marrow and become fully mature RBCs within the
circulation, expressing adult forms of hemoglobin (α2β2)
and delivering oxygen to tissues of the body. They circulate
for about 120 days before they are engulfed by macrophages
and recycled (Figure 1)[ 5, 7].
Erythrocytes can be derived in vitro from a variety of
primary stem cell sources including umbilical cord blood
(CB), peripheral blood (PB), and bone marrow (BM) [8, 9].
Despite their utility, these primary cells still represent donor-
limited sources of blood substitutes. Human embryonic
stem cells (hESCs) represent an alternative stem cell source
for generating RBCs, one whose capacity for in vitro
expansion far exceeds that of BM, PB, or even CB. Two
diﬀerent in vitro diﬀerentiation methods have been widely
used to generate RBCs from hESCs: (1) embryoid body
(EB) formation whereby hESCs are initially allowed to
cluster and form three-dimensional spheres prior to creating
single cell suspensions or (2) coculturing hESCs on top of
animal stromal feeder cell layers. For example, Chang et al.
successfully used an EB method to generate erythroid cells
from hESCs. The resulting RBCs still had not enucleatedStem Cells International 3
after 30–56 days in culture and mainly expressed embryonic
ε- and fetal γ-globins instead of the desired adult β-globin
[10]. In another study, Olivier et al. used sequential stroma
coculture steps to produce hESC-derived erythrocytes. In
the ﬁrst step, FH-B-hTERT stroma (human fetal liver cells
immortalizedwiththecatalyticsubunitoftelomerasereverse
transcriptase) was used to induce initial diﬀerentiation of
hESCs towards the hematopoietic lineage while MS5 cells
(murine BM stroma cells) were used to further induce their
diﬀerentiation towards erythrocytes. Despite their careful
multistep approach and large yields (0.5 to 5 × 107 cells),
the resulting cells had similar problems to those generated
by the EB method; they mainly expressed embryonic ε and
fetal γ globin isoforms, with only a limited amount of adult
β-globin being detectable [11].
Our recently developed “hemangioblast” system oﬀers a
clinically adaptable alternative to the above two methods and
hasproventobeusefulforthelarge-scalegenerationofRBCs
from hESCs [12–14]. Hemangioblasts (HBs) serve as the
common precursor to both hematopoietic and endothelial
cell lineages and therefore would be slightly upstream of
HSCs in the hematopoietic hierarchy depicted in Figure 1.
We found that hESCs can diﬀerentiate into HBs using a
serum-free methylcellulose-based medium. Going through
an intermediate HB stage prior to further diﬀerentiation
enables a large expansion of multipotent cells and facilitates
large-scale production of mature cell populations further
downstream. We generated approximately 1010 to 1011
erythroid cells per six-well plate of hESCs using this system
[14], which is over a thousandfold more eﬃcient than the
method reported above by Olivier et al. [11]. Extended in
vitro culture on OP9 stromal cells facilitated enucleation in
up to 65% of our cells and increased the expression of adult
β-globin, allowing it to occur in up to 15% of the cells.
Despite this improvement, the majority of cells were still
found to express fetal and embryonic globin chains.
Several groups, including our own, have demonstrated
that human iPSCs can be used to generate erythrocytes [15–
18]; however, our study also revealed that virus-transduced
iPSCs contain intrinsic molecular and cellular abnormalities
that may hinder their clinical applicability [18]. An alterna-
tive approach for RBC generation that bypasses the need for
pluripotent stem cells altogether has recently been described
[19]. Szabo et al. used ectopic Oct4 to transdiﬀerentiate
ﬁbroblasts directly to CD45+ hematopoietic progenitors and
by exposing them to EPO were able to produce erythroid
lineage cells that expressed high levels of adult β-globin and
l o wl e v e l so ff e t a lε-globin and were capable of enucleation
[19]. Further investigation will be required to determine
which starting cell source, hESCs, iPSCs, or Oct4-transduced
ﬁbroblasts, will be the most useful for the development of in
vitro generated RBC substitutes.
3.Platelets
Platelets (thrombocytes) play a central role in hemostasis
(the stoppage of blood loss at sites of vascular injury) and
vascular repair. Their concentration of ∼3 × 1011/L makes
them the second most abundant cell type in the peripheral
blood, behind only RBCs (Figure 2)[ 4]. Platelets have a
rather short lifespan compared to RBCs though and last
only ∼9d a y si nt h ec i r c u l a t i o n[ 5]. A serious condition
called thrombocytopenia (platelet counts are <5 × 1010/L)
can occur if platelet production is somehow defective as in
patientswithliverfailureorleukemia,orifplateletsarebeing
destroyed, as in patients undergoing chemotherapy [20].
Platelettransfusionscanbegiventothosesuﬀeringfromlife-
threatening thrombocytopenia, yet transfusable platelets are
often in short supply due to high demand and limited shelf
life [20]. The inadequacies of donor-dependent programs
have caused scientists and clinicians to become increasingly
interested in developing alternative sources for functional,
transfusable platelets.
With no nucleus or DNA, platelets are actually cell
fragments, being generated through the shearing and frag-
mentation of large, multinucleate megakaryocyte (MK) pre-
cursors. MKs arise in the bone marrow and share a common
precursor with RBCs, the MEP (Figure 1). Progressive com-
mitment of MEPs to the megakaryocyte lineage is principally
regulated by thrombopoietin (TPO) and involves an increase
in expression of the cell surface markers CD41 (αIIb/β3
integrin, or glycoprotein GPIIb/IIIa) and components of the
GPIb/V/IX surface complex. Megakaryopoiesis also involves
a substantial increase in cell size (50 to 100μm in diameter)
caused by the cytosolic accumulation of platelet-associated
proteins like von Willebrand Factor (vWF) [21]a n dn u c l e a r
polyploidization, resulting in the accumulation of up to
128N in DNA content [21, 22]. Cellular processes on the
polyploid MK body called “proplatelets” begin to appear,
and their eventual fragmentation and release results in the
generation of platelets (Figure 1). The mechanism of platelet
generation from MKs (thrombopoiesis) is not completely
understoodbutappearstobeextremelyeﬃcientinvivo,with
2,000–11,000 platelets being produced per MK [23].
In vitro megakaryopoiesis and thrombopoiesis was ﬁrst
reported in 1995 using CD34+ HSCs as a starting cell
source [24], and several other studies have conﬁrmed that
hematopoietic stem/progenitors isolated from PB, BM, and
CB are capable of producing MKs and functional platelets
using standard cell culture methods [25–27]. In an attempt
to recapitulate the BM microenvironment and provide more
natural growth conditions, novel three-dimensional culture
systems have recently been developed [28]. In one of these
systems, researchers used surgical grade woven polyester
fabric to create a 3D matrix within wells. In an improved
system, the same research group used inverted colloidal
crystals and polyacrylamide hydrogel to create a highly
porous, highly interconnected network of spherical cavities
within a 3D bioreactor. CD34+ cells were found to expand
and diﬀerentiate into MKs and platelets within both 3D
systems. Despite bioengineering advances, the limited in
vitro expansion capabilities of primary CD34+ cells make
these cells unable to replace donation as the principle source
of platelets. hESCs may therefore be a better starting cell
population for large-scale in vitro production.
The ﬁrst study to report the in vitro production of MKs
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method [29], yet the MKs produced rarely generated any
proplatelet-like structures. Since then, Takayama et al. has
reported the successful generation of both MKs and func-
tional platelets from hESCs and, more recently, from iPSCs
[30, 31]. They cocultured hESCs or iPSCs on C3H10T1/2
stromal cells for 14-15 days, handpicked saclike structures
containinghematopoieticprogenitorsandreplatedsinglecell
suspensions onto fresh stroma in medium containing TPO,
stem cell factor (SCF), and heparin for 9–23 days. Polyploid,
CD41a/CD42b double positive MKs, emerged from these
cultures and produced platelets containing characteristic
morphology, as assessed by electron micrography [30].
Avarietyofinvitrotestsconﬁrmedplateletfunctionality,and
a laser-induced vascular injury model was used to show that
their iPSC-derived platelets readily incorporate into newly
developing thrombi in vivo [31].
The use of both serum and animal feeder layers
throughout these studies hinders the ability of this method
to be adapted for clinical use and handpicking ES sacs
adds considerable time and labor to the process as well.
Alternative methods will likely have to be developed for
clinical grade, large-scale production. Towards this end, we
have been able to use the HB system described above for
RBCas an alternative, serum- and feeder-free method forthe
generation of MKs (Figure 3)[ 32]. Yet, similar to Takayama’s
studies, we also found that eﬃcient platelet generation from
MKsstillrequiresconventionalstromacoculture.OurhESC-
derived platelets showed the ability to adhere to and spread
on ﬁbrinogen, vWF, and type I collagen-coated surfaces, to
aggregate when stimulated with physiological agonists, and
to retract ﬁbrin clots in vitro. A laser-induced thrombosis
model also conﬁrmed that our hESC-platelets were capable
of contributing to newly forming thrombi in vivo [32]. If in
vitro diﬀerentiated hESCs are to become a major source of
transfusable platelets, future work will be needed in order to
determine a way to eliminate the need for stroma during the
MK to platelet step and to increase the eﬃciency of in vitro
thrombopoiesis as well.
4.WhiteBloodCells:DendriticCells
Whitebloodcells(WBCsorleukocytes)onlyrepresentabout
1% of the cells within the peripheral blood [4] (Figure 2),
yet they play extremely important roles in protecting the
body against viruses, bacteria, and the outgrowth of cancer
cells. Straddling the interface between innate and adaptive
immunity, dendritic cells (DCs) are one of the body’s three
main types of professional antigen-presenting cells (APCs).
DCs can stimulate speciﬁc T-cell responses against a variety
of disease-associated antigens and therefore, may be used in
the development of vaccine-based therapies [33, 34].
Human DCs originate from HSCs and can develop
through both myeloid and lymphoid lineage differentia-
tion pathways [35]. Myeloid (m) DCs arise from gran-
ulocyte-monocyte progenitor- (GMP-) derived monocytes
(Figure 1). They secrete interleukin (IL)12 in response to
activating stimuli and express toll-like receptors TLR2 and
TLR4. Lymphoid lineage-derived DCs (plasmacytoid (p)
DCs) have similar functional characteristics to mDCs, but
4 ×109 −1 ×1010 WBCs
3 ×1011 platelets
5 ×1012 RBC
monocytes,
macrophages, DCs
granulocytes
NK cells
Bc e l l s
Tc e l l s
Figure 2: Number and type of cellular blood components per liter
of human peripheral blood. hESCs and/or iPSCs may be able to
serve as cost-eﬀective, readily available substitutes for these various
components of the peripheral blood. Both RBCs and platelets
are frequently used in transfusions, but these donor-derived PB
components are often in short supply. WBCs represent a very small
percentage of PB cells, yet they serve critical functions in protecting
the body from various microbes and cancer cells. They may be used
in future cell-based therapies against cancer or HIV.
secrete interferon (IFN) α, and express TLR7 and 9 [35].
Immature DCs survive for weeks, sampling their surround-
ing environment in the skin, nose, lungs, gut, or peripheral
blood and using TLRs for pattern recognition on various
types of pathogens. Once in contact with a suitable antigen,
immature DCs become activated and undergo the process
of maturation, which involves proteolysing an antigen and
presentingitsfragmentsontheDCsurfaceusingMHCclassI
orIImolecules.Italsoinvolvesanupregulationintheexpres-
sion of T-cell costimulatory receptors such as CD80 (B7.1),
CD86(B7.2)[36],andCD40[37].MaturingDCsalsoupreg-
ulate expression of CCR7, a chemotactic receptor that helps
them migrate through the bloodstream to the spleen or into
thelymphaticsystem[38].FullymatureDCsonlysurvivefor
a few days which is enough time for them to travel to the
lymph nodes and activate helper T cells, killer T cells, and B
cells.
Innovativeworkperformedinthelate1990sprovidedthe
proof of concept for clinical use of DCs as studies showed
that ex vivo generated DCs (from allogenic or autologous
BM or PB sources) could be loaded with melanoma-speciﬁc
antigens and stimulate antitumor immune responses once
injected into patients [39, 40]. Since then, other studies have
shown that DCs exposed to killed tumor cells can also elicit
speciﬁc cytotoxic CD8+ T-cell responses [41]. Given their
powerful immunostimulatory eﬀects, over 200 clinical trials
are currently underway to explore the safety and eﬃcacy of
DC-based vaccines for diseases such as melanoma, multiple
myeloma,typeIdiabetes,HIV,andhepatitsCviralinfections
(http://www.clinicaltrials.gov/).Stem Cells International 5
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Figure 3: A hemangioblast (HB) diﬀerentiation system may be used to generate mature blood cells from hESCs/iPSCs. Pluripotent hESCs
or iPSCs are ﬁrst diﬀerentiated into EBs using a deﬁned serum-free medium (Stemline II, Invitrogen) and vascular endothelial growth
factor (VEGF), bone morphogenic protein 4 (BMP4), and basic ﬁbroblast growth factor (bFGF). After 4 days, EBS are disrupted and single
cell suspensions are replated into a serum-free, methylcellulose-based semisolid growth medium containing granulocyte colony-stimulating
factor (G-CSF), GM-CSF, IL3, IL6, SCF, FL, VEGF, TPO, and bFGF for the generation of small, spherical, HBs (all images, 10x). After
6–8 days, HBs are harvested and grown in liquid culture containing the indicated cytokines in order to produce RBCs and platelets. For
RBCs, subsequent coculture on stroma enhances enucleation and β-globin switching. For platelets, HBs are ﬁrst diﬀerentiated into MKs in
a stroma-free manner. Subsequent stroma coculture facilitates generation of functional platelets from the MKs.
InApril2010,Provenge(SilpuleucilT,developedbyDen-
dreon) became the ﬁrst DC-based vaccine therapy to gain
full FDA approval and is a treatment option for patients with
metastaticcastration-resistantprostatecancer[42].ThisDC-
based vaccine utilizes an antigenic peptide derived from
prostatic acid phosphatase fused to the cytokine granulocyte
macrophage colony-stimulating factor (GM-CSF) for highly
eﬃcient delivery and uptake by ex vivo cultured autologous
DCs [43]. Given the high cost of tailor-made autologous
or allogenic DC-based vaccines like Provenge [44], hESCs
may serve as a cost-eﬀective alternative cell source for the
derivation and large-scale manufacture of antigen-primed
DCs.
Slukvin et al. were the ﬁrst group to produce functional
DCs from hESCs and did so by using a 3-step diﬀerentiation
protocol adapted from the mouse ESC system [45]. They
cocultured hESCs on OP9 stroma cells for 9-10 days
to promote initial hematopoietic diﬀerentiation and then
transferred cells to suspension culture consisting of αMEM,
10% fetal calf serum, and GM-CSF for the next 8–10 days.
Live cells were puriﬁed and cultured in medium containing
GM-CSF + IL4 for an additional 7–9 days, during which
time human DCs emerged. Two other groups have since
reported the generation of hESC-derived myeloid-lineage
DCs using EB formation and have done so in a serum-free or
serum-andfeeder-freemanner[46,47].ThesehESC-derived
DCs had characteristic large eccentric nuclei, spiny dendritic
processes and expressed DC surface markers CD11c, CD40,
CD45, CD86, HLA class I, and HLA class II to varying
degrees. Yields ranged from 2 DCs per hESC in one study
[46]t o3 – 5D C sp e rh E S C si nam o r er e c e n ts t u d y[ 47].
Despite subtle diﬀerences compared to monocyte-derived
DCs, hESC-derived DCs appear to be functional upon
maturation in assays measuring IL12p70 secretion, chemo-
taxis, antigen-uptake and proteolysis, induction of T-cell
proliferation, and stimulation of antigen-speciﬁc cytotoxic
CD8+ T-cell responses [46, 47].
When developing hESC-based DC vaccines, maturation
cocktails will need to be carefully chosen in order to elicit the
desired response in vivo. For example, prostaglandin E2 has
been shown to facilitate DC chemotaxis, yet it inhibits the
ability of DCs to secrete IL12p70 [48, 49]. This distinction
would have important consequences for DC-based therapies
in vivo since IL12p70 is essential for driving CD4+ Tc e l l s
towards a proinﬂammatory, antimicrobial Th1 response and
away from the opposing anti-inﬂammatory Th2 response.
Clinical application of hESC-derived DC vaccines will also
dependupontheirperformanceinpreclinicalanimalstudies.
In vivo, preclinical testing of hESC-DCs has not yet been
reported, but studies performed with antigen-loaded autolo-
gous or allogenic DCs should provide a useful guide.
5.WBCs: NaturalKiller Cells
Human natural killer (NK) cells are generated from HSC-
derived CLPs (Figure 1) and have a half-life of ∼7–10
days in the PB [50]. Their concentration of 1 × 108 cells/L
comprises ∼1-2% of WBCs, or 0.01-0.02% of all cells in
the PB [4]. NK cells belong to the innate immune system
and provide rapid, nonspeciﬁc responses against various
microbial infections and contribute to tumor cell detection
and elimination [50]. NK cells mount a protective response6 Stem Cells International
if they encounter a cell with insuﬃcient MHC I expression,
yet, to prevent inappropriate cell killing, the procedure for
surveying MHC I expression is rather complex. In brief, if
ac e l ll a c k ss u ﬃcient self-MHC I molecules, interplay
between various activating and inhibitory signals helps
NK cells mount an appropriate protective response, either
cytokine release, natural cytotoxicity or antibody-dependent
cellular cytotoxicity (ADCC) [51].
The two main populations of NK cells, immature and
mature, are functionally distinct and can be discerned
based upon expression of various cell surface mark-
ers. Immature NK cells have high cytokine production
capacity and low cytotoxicity potential and are typi-
cally CD56bright/CD16low/KIRlow/CD94high [52]. Secretion
of cytokines by immature NK cells activates macrophages
and helps initiate a broad immunological response. In
contrast, mature NK cells display low cytokine pro-
duction capacity and high cytolytic potential and are
CD56dim/CD16high/KIRhigh/CD94low [52]. Their cytolytic
functions depend upon the release of granzyme and perforin
enzymes from internal granules, which in turn are respon-
sible for lysing and inducing apoptosis in target cells. The
transition from immature to mature NK cells is thought to
arise in secondary lymphoid tissues, yet the vast majority of
NKcellsinthePBarethematureCD56dim CD16high cytolytic
type [53].
Endogenous NK cells may not detect and eliminate
cancer cells in vivo. In many patients, NK cell activity may
be reduced or defective, while in others, cancer cells have
developed mechanisms to evade NK cell detection (reviewed
in [51]). Nonetheless, studies published in the 1980s by
Rosenberg and colleagues showed that infusions of autol-
ogous lymphokine-activated killer (LAK) cells stimulated
ex vivo with IL2 were able to shrink tumors in patients
with a variety of diﬀerent types of cancer [54, 55]. This
groundbreaking work stimulated considerable interest in
using NK cells clinically and a variety of approaches for
harnessing their cytotoxic capabilities. While the details of
these studies are reviewed elsewhere [51], ex vivo stimulation
and infusion of autologous or allogenic NK cells has been
used in experimental therapies for many diﬀerent types of
cancers, and alterations to clinical protocols have increased
the success of this therapeutic approach. Currently, over
200 clinical trials are being performed to evaluate the safety
and eﬃcacy of NK cell-based immunotherapy for leukemia,
lymphoma, melanoma, glioma, renal cell carcinoma, and
cancers of the breast, pancreas, lungs, head, and neck
(http://www.clinicaltrials.gov/). Results of these trials will
help establish the most eﬀective strategies for harnessing
NK immunotherapeutic potential. The biggest hindrance to
these adoptive transfer approaches thus far appears to be the
diﬃculty in obtaining suﬃcient numbers of NK cells from
peripheral blood mononuclear or LAK cell collections [51].
The use of hESCs for in vitro generation of NK cells may
provide larger pools of suitable eﬀector cells and thus be able
to overcome this hurdle.
In general, the diﬀerentiation of hESCs into lymphoid
lineage cells has proven to be more diﬃcult than their
diﬀerentiation into myeloid lineage cells. Only one group,
led by Dan Kaufman at the University of Minnesota, has
been able to successfully and reproducibly derive functional
NK cells from hESCs [56, 57]. Their optimized 2-step diﬀer-
entiation procedure begins by coculturing undiﬀerentiated
hESCs on M210-B4 (a mouse BM-derived stroma cell line
that expresses laminin and collagen IV) for 17–20 days.
CD34+/CD45+ double positive cells, which represent <5% of
all cells, are then isolated from the culture and transferred
onto AFT024 stroma in medium containing SCF, ﬂt3-ligand
(FL), IL7, and IL15. A highly enriched homogenous pop-
ulation of CD45+CD56+CD94+ NK cells typically emerges
after 30–35 days. In vitro assays showed that hESC-derived
NK cells produced in this manner were capable of secreting
IFNγ inresponsetoIL12/IL18stimulationandalsodisplayed
potent natural cytotoxicity against K562 erythroleukemia
cells and ADCC against Raji cells [56]. These hESC-NK
cells were subsequently shown to harbor natural cytotoxicity
against other types of cancer cells and displayed in vivo
antitumor activity in a xenograft mouse model [57]. More
r e c e n t l y ,t h i ss a m eg r o u ph a sb e e na b l et os u c c e s s f u l l y
produce functional NK cells from iPSCs and showed that
they harbor anti-HIV activity [58]. Despite these exciting
ﬁndings, the requirement for two diﬀerent types of stroma
c o c u l t u r ea sw e l la st h en e e dt oi s o l a t er a r eC D 3 4 / C D 4 5
double positive cells limits the utility of this approach
for large-scale, cost-eﬀective, clinical grade production of
hESC/iPSC-generated NK cells. Further optimization will
need to be performed before such hESC/iPSC-derived NK
therapies can move into clinical trials.
6. WBCs: T Cells
As part of the adaptive immune system, T cells develop
in the thymus and can be stimulated to mount antigen-
speciﬁcimmuneresponsesagainstavarietyofpathogensand
cancer cells. They are present at a concentration of ∼1 ×
109 cells/L of peripheral blood, thus representing ∼10% of
WBCs or 0.1% of all circulating blood cells (Figure 2)[ 4].
While a detailed background on T-cell biology is beyond
the scope of this paper, T cells can generally be divided
into ﬁve main subtypes based on function and cell surface
marker expression: eﬀector or memory helper CD4+ T
cells [59]; eﬀector or memory cytotoxic CD8+ T cells [59];
immunosuppressive regulatoryT cells(Tregs) [60]; skin, gut,
or lung-resident γδ T cells [61]; rare, CD1d-restricted NK T
cells [62].
Clinical interest in T cells as therapeutic agents largely
revolves around the isolation and ex vivo expansion of
speciﬁc antigen-responsive helper and/or cytotoxic T-cell
subsets in order to generate a highly speciﬁc immune
response once infused into a patient. CD4+ helper T cells
will secrete particular cytokines in response to MHC
II-presented antigens while CD8+ cytotoxic T cells will
respond to MHC I-presented antigens and unload cytotoxic
enzymes to induce apoptosis in antigen-expressing target
cells. Adoptive T-cell therapy (ACT) was ﬁrst described in
1988 as a treatment option for melanoma [63], and many
improvements have been and are still being made to increase
the utility, safety, and eﬃcacy of ACT protocols [64–66].Stem Cells International 7
For example, hundreds of tumor-associated antigenic pep-
tides have been cloned [66] and enable the use of peptide-
pulsed APCs to stimulate T cells in vitro prior to their use
in patients. This approach has successfully been used to
produce antigen-speciﬁc T cells for treating melanoma, HIV,
leukemia, and other diseases [67–69]. Another strategy that
is being developed to improve ACT protocols involves the
use of genetic engineering to clone and artiﬁcially express
antigen-speciﬁc T-cell receptors (TCRs) in autologous T-cell
populations. This approach has been used successfully to
treat melanoma [70, 71] and is being developed for use in
HIV and leukemia therapies [72, 73].
The risks and complexities involved in exploiting the
adaptiveimmunesystemmakeT-cell-basedtherapiesincred-
ibly expensive and still largely experimental. However, as
exempliﬁed above, the power of ACT is large enough to
warrant eﬀorts that might be able to streamline the therapy
or make it more cost eﬀective. Towards this end, several
groups have devised protocols to diﬀerentiate T cells from
pluripotent human cell sources.
Extrapolating from results in various mouse studies, the
use of immobilized Notch ligand, such as delta-1 (DL1),
h a sp r o v e nt ob ea ne ﬀective strategy for lymphopoietic
diﬀerentiation of human pluripotent cells [74–76]. For
example, Awong et al. showed that DL1-expressing OP9
stroma allowed CD34+ CB cells to diﬀerentiate into CD7+
T-cell progenitors. These pro-T cells could engraft into the
thymuses of NOD/SCID/γc−/− (NSG) mice and continue
diﬀerentiating down the T-cell lineage [75].
T h eﬁ r s tr e p o r tt h a th E S C sc o u l db ed i ﬀerentiated into
T cells was published in 2006 [77]. Gali´ c et al. cultured H1
hESCsonregularOP9cellsfor7–14days,whereuponCD34+
cells were isolated and injected into a Thy/Liv implant within
SCID or RAG2−/− mice. The hESC-derived cells were found
to diﬀerentiate into T cells within the thymus-like Thy/Liv
environment [77]. Gali´ c et al. switched to an EB-based
method three years later and noted improvements in the
Thy/Liv-generated, hESC-derived T cells [78]. CD4+/CD8+
double positive cells began to appear within 4 weeks while
CD4+ single positive and CD8+ single positive cells that had
undergone TCR rearrangements emerged within 8 weeks
[78].
Another study published in 2009 showed that mature
T cells could be obtained from hESCs using a completely
in vitro culture system [79]. Timmermans et al. cocultured
H1 hESCs on OP9 cells in αMEM plus 20% fetal calf serum
for 12 days and observed the appearance of “hematopoietic
zones,”whichappeartobesimilartotheESsacsdescribedfor
megakaryocytegeneration.TheyisolatedCD34hiCD43lo cells
from these zones and replated them onto DL1-expressing
OP9 cells for 5 to 7 weeks in the presence of FL, SCF,
and IL7. CD45+CD7+CD117+cyCD3e+ T-cell progenitors
emerged within 6 days while CD4+/CD8+ double positive
cells emerged from a larger CD3e+CD5+ population within
14 days. After 30 days, CD3+ T cells that had undergone
TCR rearrangements were present and found to be func-
tional in assays examining their proliferation in response
to phytohemagglutinin and IFNγ production [79]. In total,
these diﬀerentiation protocols for T-cell generation have the
potential to be further developed for use with iPSCs, and one
day will hopefully be applicable to ACT protocols for human
immunotherapy.
7.Other WBCs:GranulocytesandB Cells
Other leukocyte populations, including granulocytes (neu-
trophils, eosinophils, basophils) and B cells, may have
utility as hESC-based therapies; however, interest in and/or
development of these cell populations has not been as great
as for other blood cell components. In vitro diﬀerentiation
of hESCs down the B-cell lineage has been demonstrated
in theory [80], yet detailed work is still needed in order to
optimize diﬀerentiation conditions and functionally charac-
terize the resulting cells. For granulocytes, the expense and
diﬃculty in bringing hESC-based therapies to the clinic may
not be warranted. For example, neutrophils are chemotactic
phagocytes that migrate to sites of infection and provide
protection against bacteria. Neutropenia (neutrophil counts
less than 5 × 108 cells/L) can cause an aﬄicted individual to
be at higher risk for developing infections. While allogenic
neutrophil transfusions were shown to alleviate the risk
of infections over thirty years ago, the use of antibiotic,
antiviral, and/or antifungal therapies has largely replaced
them in the clinic [81].
Nonetheless, two studies published in 2009 describe the
u s eo fa nE B - b a s e dm e t h o di no r d e rt og e n e r a t eC D 1 1 b +
neutrophils from KhES hESCs [82, 83]. These hESC-derived
neutrophils expressed varying levels of other neutrophil cell
surface markers and were slightly larger than those from the
peripheral blood [83]. Despite such subtle diﬀerences, they
werefoundtobefunctionalinthreeinvitroassaysevaluating
chemotaxis, phagocytosis, and production of reactive oxygen
species [82, 83]. One study also showed in vivo chemotaxis
of hESC-derived neutrophils in response to IL1β expressed
in an air-pouch inﬂammatory mouse model [82]. It remains
to be determined whether or not hESC-neutrophils (or
other types of granulocytes) will ever be developed for
use as transfusion reagents, but in vitro diﬀerentiation
systems for their generation may be useful for delineating
cytokine requirements for hematopoietic diﬀerentiation,
drug screening eﬀorts, or elucidating molecular details of
certain inherited diseases.
8. Concluding Remarks andPerspectives
Peripheral blood components have many diﬀerent therapeu-
tic applications, and hESCs have garnered a lot of interest as
a renewable cell source that can be used for their generation.
From RBCs and platelets being used in transfusions to treat
cytopenias to DCs, NK cells, and T cells being used in
immunotherapies to treat cancer and HIV, hESCs may be
useful for generating these mature cell types in abundant
supplies and in cost-eﬀective ways (Table 1). Furthermore,
iPSCs may be able to generate these mature cell types from
a patient’s own cells, thus reducing immunological barriers
that plague cell-based therapies.
The ﬁeld of regenerative medicine is still in its infancy,
yet some hESC-based therapies are starting to be tested in8 Stem Cells International
Table 1: Utility and current status of hESC/iPSC-derived blood components.
Cell type Therapeutic use Diﬀerentiation method Advantages Disadvantages
Erythrocytes
(RBCs)
Transfusions for severe
anemia or blood loss
EBs, HBs, and/or stroma
coculture
Potential for alleviating
shortages; production of
pathogen-free (O)Rh−
“universal donor” RBCs
Ineﬃcient enucleation;
diﬃculties in switching to
adult-type (beta) globin forms
Platelets Transfusions for critical
thrombocytopenia
Handpicking ES sacs with
2-step stroma coculture or
HB method with 1-step
stroma coculture
Potential for alleviating
supply shortages due to
high demand and limited
shelf-life
Reliance on stroma and
ineﬃciency/poor yield in MK to
platelet diﬀerentiation step
Dendritic cells Antigen-speciﬁc vaccines
f o rc a n c e ro rH I V
EBs, serum- and
stroma-free culture
conditions
Cost-eﬀective oﬀ-the-shelf
potential; stimulates
antigen- speciﬁc T-cell
response
Animal models needed to test in
vivo eﬃcacy; may cause
undesired side eﬀects
Natural killer
cells
Natural or
antibody-assisted
anticancer cytotoxicity
EBs with 2-step
stroma-coculture and
sorting of rare
CD34+/CD45+ cells
Animal models suggest
hES-derived NKs are highly
eﬀective
Reliance on 2 steps of stroma
coculture; need for sorting may
hinder clinical scaleup
Tc e l l s
antigen-speciﬁc anticancer
or anti-HIV adoptive cell
transfer
handpicking hematopoietic
zones and 2-step stroma
coculture including delta
ligand expression
Cost-eﬀective oﬀ-the-shelf
therapeutic potential
Not eﬃcient, needs further
study; complex biology and high
in vivo risks
clinical trials. As of late 2010, two hESC-based therapies
have been granted Investigational New Drug (IND) status
by the FDA and have just recently entered (or will soon
be entering) phase I/II clinical trials. Geron’s GRNOPC1,
consisting of hESC-derived oligodendrocyte progenitor cells,
is being tested in clinical trials for treating subacute thoracic
spinal cord injuries (http://www.geron.com/). Advanced
Cell Technology’s hESC-derived retinal pigment epithelium
(RPE) cells (http://www.advancedcell.com/)w i l ls o o nb e
tested in 2 clinical trials. The ﬁrst trial is for the treatment of
advanced Stargardt’s Macular Dystrophy, a form of juvenile
macular degeneration that often leads to blindness, and the
second trial is for dry age-related macular degeneration. The
safetyandeﬃcacyofthesetherapiesinearlyclinicaltrialswill
likely have a signiﬁcant impact on the development of other
types of hESC-based therapies as well as the policies of the
FDA towards the use of any hESC-derivatives to treat human
disease.
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